An overview from John P. Roberts, M.D.
Professor & Chief, Division of Transplant Surgery, UCSF Liver Transplant Program
A gift to the UCSF Department of Surgery can help physicians and scientist find treatments and cures for serious liver diseases such as hepatitis B & C, and liver cancer.
The FDA has approved two new medications, Incivek and Victrelis, for treatment of hepatitis C. These drugs mark a new direction in treatment and significant improvement over the current standard of care.
Building on its established strengths in research, clinical care, hepatology and transplant medicine, UCSF is at the threshold of an exciting era of improved care and discovery of advanced treatments for liver disease. As one of the oldest and most respected programs in transplantation, UCSF has served as a benchmark for transplant centers world-wide. The liver transplant program is one of the nation's largest, with a 92% one-year survival rate (compared with the national average of 87%), achieving excellent outcomes even among high-risk patients.UCSF has a thriving clinical trials program offering patients a broad portfolio of trials for liver diseases led by world-renowned Principal Investigators (PI).
We have developed LiverSource to share that knowledge and experience, and to provide a comprehensive online guide to resources on the web related to awareness, prevention, diagnosis, treatment and research. Among the areas explored on LiverSource are: